AstraZeneca Pharma India Ltd. has announced a meeting of its Board of Directors on February 11, 2026, to consider and approve the unaudited financial results for the quarter ended December 31, 2025 (Q3). The company has also declared that the ‘Trading Window’ remains closed for all designated persons from December 16, 2025, to February 13, 2026.
Board Meeting Announcement
AstraZeneca Pharma India Limited has scheduled a meeting of its Board of Directors to be held on Wednesday, February 11, 2026. The primary agenda of this meeting is to review and approve the unaudited financial results for the fiscal quarter concluding on December 31, 2025.
Trading Window Closure
In accordance with company policy and regulatory guidelines concerning insider trading, AstraZeneca Pharma India Limited has declared the ‘Trading Window’ closed for all Designated Persons. This restriction is effective from December 16, 2025, and will remain in place until February 13, 2026 (inclusive). This measure ensures compliance with the company’s Code of Conduct for Prevention of Insider Trading.
Source: BSE
